ClinicalTrials.gg
CompletedNCT03068884Updated Feb 22, 2018

Dopamine Dorsolateral Prefrontal Cortex Behavioural Flexibility

An interventional study of Cathodal Transcranial direct current stimulation and L-Tyrosine in Cognitive Change, sponsored by Sheffield Hallam University. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by Sheffield Hallam University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

Behavioural or cognitive flexibility (BF) is an essential ability which allows an organism to adaptively change responses in accordance with feedback of results. In humans, this ability is disrupted among those who suffer a variety of neurological and psychiatric conditions including Parkinson's disease, schizophrenia, addiction, obsessive compulsive disorder and autism. Additionally, there is evidence of substantial individual differences in BF within the healthy population.

Two known neurobiological mechanisms which relate to BF performance are variation in dopamine (DA) and serotonin (SE) function. One particular brain regions which has been heavily implicated in BF is the prefrontal cortex (PFC), with the dorsolateral PFC receiving a largely DA innervation and the dorsomedial PFC a SE input. Studies have demonstrated that damage to parts of PFC including the orbitofrontal cortex (OFC), for example, impairs reversal learning (a form of BF) whereas lesions of the dorsolateral PFC affect attentional set-shifting (another measure of BF).

In humans, putative augmentation of DA efflux via administration of the DA and norepinephrine precursor tyrosine has been shown to improve task-switching performance, and inhibitory control suggesting a causal role of DA in regulating BF. Similarly, putative depletion of serotonin neurotransmission via tryptophan depletion procedures has been shown to reduce the BOLD response during performance monitoring and increase perseverative behaviour.

One important strategy (in humans) to observe whether the PFC is causally involved in BF performance, is by reversible electrical stimulation of the PFC, so that PFC cells could be inhibited or excited while a participant is performing a BF task. In recent years, several laboratories have taken advantage of a relatively new technology known as transcranial direct current stimulation (tDCS) to study the relationship between brain function and behaviour. Using this technique, increases or decreases in cortical excitability are partly determined by the polarity of the stimulation; increases occur under the anode electrode whereas decreases occur under the negatively charged cathode.

Using this approach, several studies have shown that anodal and cathodal stimulation over the PFC can have a number of effects on BF performance, with general improvements during anodal stimulation and impairments during cathodal. If this is the case, one important step that remains to be understood is whether dopamine and serotonin are causally related to these outcomes when neurons of the dLPFC/dMPFC are either excited or inhibited via tDCS.

Thus, the specific novelty of this study rests in combining a psychopharmacological approach (i.e. tyrosine/tryptophan loading) with selective neuroanatomical (i.e. dorsolateral/dorsomedial prefrontal cortex) inhibition of cells via tDCS while participants are performing BF tasks. By doing so, we will be able to establish whether increased dopaminergic/serotonergic output to the PFC is a necessary requirement for BF performance.

02

Conditions studied

  • Cognitive Change
03

In context

Lead sponsor

Sheffield Hallam University is the lead sponsor of 48 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 30 years
  • In good health
  • Agrees to fast overnight prior to testing

Exclusion criteria

Exclusion Criteria:

  • Presence of cardiac, hepatic, renal, or neurological disorders
  • Presence of damaged or diseased skin on your face and scalp, or a sensitive scalp
  • A history of alcohol or drug addiction, or severe psychiatric illness
  • Taking drugs which may lower seizure threshold (i.e. epilepsy)
  • In a state of pregnancy
  • Having slept less than 6 hours the night before testing
  • A history of migraine or headaches
  • A history of taking antidepressants
  • A history of taking tyrosine supplements
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Sham comparator
    Tdcs sham

    Dietary Supplement: L-Tyrosine · Dietary Supplement: Cellulose (placebo)

  • Placebo comparator
    Placebo

    Device: Cathodal Transcranial direct current stimulation · Device: Transcranial direct current stimulation (sham)

  • Experimental
    Tdcs cathodal

    Dietary Supplement: L-Tyrosine · Dietary Supplement: Cellulose (placebo)

  • Experimental
    Tyrosine

    Device: Cathodal Transcranial direct current stimulation · Device: Transcranial direct current stimulation (sham)

Interventions

  • DeviceCathodal Transcranial direct current stimulation

    Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

  • Dietary supplementL-Tyrosine

    Administration of 2 grams tyrosine

  • DeviceTranscranial direct current stimulation (sham)

    Sham tDCS

  • Dietary supplementCellulose (placebo)

    Administration of 2 grams cellulose

06

What researchers measure

Primary outcomes

  1. Wisconsin Card Sorting task

    Total Number of errors (e.g. 1-200)

    Time frame: 2 hours for each of the four conditions

  2. Probabilistic reversal learning task

    Mean Errors per reversal (e.g. 1-20)

    Time frame: 2 hours for each of the four conditions

07

Study locations

1 site
  • Psychology laboratories
    Sheffield, Yorkshire S10 2BQ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03068884
Lead sponsor
Sheffield Hallam University
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
Mar 1, 2017
Primary completion
Dec 31, 2017
Completion
Jan 31, 2018
Last update
Feb 22, 2018

Study contacts

Luca Aquili, Ph.D.
principal investigator · Sheffield Hallam University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tyrosine

Start the discussion